PCSK9 and diabetes mellitus: However, PCSK9 inhibitors were primarily related to mild hyperglycaemias (n = 1587/87,724 (1.67%), adjusted ROR 1.48 (1.36–1.62)) rather than to diabetes (n = 372/87,724 (0.42%), adjusted ROR 0.67 (0.67–0.074)) [65].